Trial
NCT01841021
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Seagen Inc.
Condition
Peripheral T-Cell Lymphoma
Intervention
Brentuximab vedotin
Why stopped
Slow accrual, loss of sponsor support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-01-19